Patents Examined by Cherie M Stanfield
-
Patent number: 10125195Abstract: The present invention relates to a stable, low viscosity antibody formulation, wherein the formulation comprises a high concentration of anti-INFAR1 antibody. In some embodiments, the invention relates in general to a stable antibody formulation comprising about 100 mg/mL to about 200 mg/mL of an antibody or fragment thereof that specifically binds human interferon alpha 1 (INFAR1); about 20 mM to about 80 mM of a lysine or a salt thereof; about 0.02% to about 0.06% of a surfactant; an uncharged excipient; and a formulation buffer. In some embodiments, the invention is directed to a container, dosage form and/or kit. In some embodiments, the invention is directed to a method of making and using the stable antibody formulation.Type: GrantFiled: August 18, 2016Date of Patent: November 13, 2018Assignee: AstraZeneca ABInventors: Roberto Depaz, Natalie DeJesus, Jared Bee
-
Patent number: 10105437Abstract: The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.Type: GrantFiled: February 24, 2015Date of Patent: October 23, 2018Assignee: BTG INTERNATIONAL LIMITEDInventors: Robert Anderson, Tim Beissbath, Jason Tye Din
-
Patent number: 10094825Abstract: The invention provides methods for identifying the presence of, or an increased risk of developing, organ damage in a subject having an autoimmune disease, for example, Systemic Lupus Erythematosus (SLE) or Mixed Connective Tissue Disease (MCTD), or other disease in which the lungs and/or kidneys are involved. In one embodiment, a significantly increased combined IgM reactivity against the peptides having the sequences of SEQ ID NOs: 4, 9, 12, and 15 in a sample obtained from a patient compared to a healthy control indicates lung damage or an increased risk of developing lung damage in the subject. In another embodiment, a significantly increased combined IgM reactivity against the peptides having the sequences of SEQ ID NOs: 2, 8, 12, 14, 15, and 17, in a sample from a patient compared to a healthy control indicates kidney damage or an increased risk of developing kidney damage in the subject.Type: GrantFiled: August 1, 2016Date of Patent: October 9, 2018Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEESInventors: Annia Mesa, Jason A. Somarelli
-
Patent number: 10081683Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).Type: GrantFiled: June 7, 2017Date of Patent: September 25, 2018Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe de Romeuf, Nicolas Bihoreau, Emmanuel Nony
-
Patent number: 10066004Abstract: Inhibitor peptides for combinatorial inactivation of ErbB1, ErbB2, and ErbB3 featuring an EGFR-based peptide and a cell penetrating component such as a protein transduction domain (e.g., PTD4) for enhancing penetration of the EGFR-based peptide into a cell. The EGFR peptide may be from 8 to 30 amino acids in length. The inhibitor peptides can inhibit tumor growth, reduce metastasis, activate apoptosis, activate necrosis, disrupt calcium signaling, and/or increase ROS. In some embodiments, the EGFR-based peptide is at least 50% identical to at least 8 consecutive residues of SEQ ID NO: 1.Type: GrantFiled: April 4, 2016Date of Patent: September 4, 2018Assignee: ARIZONA CANCER THERAPEUTICS, LLCInventor: Joyce A. Schroeder
-
Patent number: 10064926Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: December 21, 2015Date of Patent: September 4, 2018Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni Weinschenk, Andrea Mahr, Jens Fritsche, Phillip Mueller, Anita Wiebe, Sara Kutscher
-
Patent number: 10060908Abstract: Low levels of antibodies reactive with oxidized Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunization and therapy of these diseases and conditions are provided.Type: GrantFiled: August 12, 2013Date of Patent: August 28, 2018Assignee: MEDIRISTA BIOTECHNOLOGIES ABInventor: Johan Frostegård
-
Patent number: 10059751Abstract: The invention relates to combinations of peptides or variants thereof derived from a portion of an amino sequence of a house dust mite allergen, e.g. the allergens Der p 1, Der f 1, Der p 2 and/or Der f 2. Such peptides comprise at least one T cell epitope and a significant high number of patients in a worldwide population will have HLA alleles with the potential to bind the peptides of the peptide combinations. The invention also relates to the use of such peptide combinations in relieving an immune response caused by a dust mite.Type: GrantFiled: December 23, 2014Date of Patent: August 28, 2018Assignees: ALK-ABELLÓ A/S, LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOGYInventors: Claus Lundegaard, Lars Harder Christensen, Peter Adler Wurtzen, Alessandro Sette, John Sidney, Gitte Lund, Peter Sejer Andersen
-
Patent number: 10047362Abstract: The present invention relates to the use of an E3 ligase RNF185 inhibitor for treating cystic fibrosis and chronic obstructive pulmonary disease.Type: GrantFiled: August 5, 2014Date of Patent: August 14, 2018Assignee: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVESInventors: Agnès Delaunay-Moisan, Michel Toledano
-
Patent number: 10047395Abstract: The disclosure provides methods for detecting and diagnosing diseases and conditions associated with defects in cardiolipin remodeling. In some embodiments, the present technology relates to methods for detecting the presence or amount of cardiolipin isoforms and/or the presence or amount of enzymes involved in cardiolipin remodeling.Type: GrantFiled: June 23, 2014Date of Patent: August 14, 2018Assignee: STEALTH BIOTHERAPEUTICS CORPInventor: D. Travis Wilson
-
Patent number: 10023654Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.Type: GrantFiled: December 13, 2016Date of Patent: July 17, 2018Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald
-
Patent number: 10022194Abstract: A system comprises a medical instrument including a rotatable capstan. The rotatable capstan includes a first coupling feature and a drive system including a rotatable drive element. The rotatable drive element includes a second coupling feature. The first and second coupling features have an aligned engagement configuration in which rotation of the rotatable drive element induces rotation of the rotatable capstan and a non-aligned engagement configuration in which rotation of the rotatable drive element does not induce rotation of the rotatable capstan.Type: GrantFiled: January 20, 2016Date of Patent: July 17, 2018Assignee: Intuitive Surgical Operations, Inc.Inventor: Giuseppe M. Prisco
-
Patent number: 9995755Abstract: Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.Type: GrantFiled: September 9, 2013Date of Patent: June 12, 2018Assignee: GENENTECH, INC.Inventors: Joseph R. Arron, Richard W. Erickson, Michelle Freemer, Meredith Hazen, Guiquan Jia, John G. Matthews, Wendy Putnam, Heleen Scheerens, Yanan Zheng
-
Patent number: 9970944Abstract: Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor.Type: GrantFiled: February 3, 2014Date of Patent: May 15, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Jochen Schmitz, Martin Oft, Robert A. Kastelein, J. Fernando Bazan
-
Patent number: 9951114Abstract: Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.Type: GrantFiled: June 4, 2014Date of Patent: April 24, 2018Assignee: Virginia Commonwealth UniversityInventors: Paul B. Fisher, Praveen Bhoopathi, Swadesh K. Das, Luni Emdad, Devanand Sarkar, Upneet Sokhi
-
Patent number: 9938332Abstract: The present invention provides a peptide-type compound which induces secretion of growth hormone and which has the activity of increasing the intracellular calcium ion concentration, wherein at least one amino acid is replaced by a modified amino acid and/or a non-amino acid compound, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 12, 2012Date of Patent: April 10, 2018Inventors: Kenji Kangawa, Masayasu Kojima, Hiroshi Hosoda, Hisayuki Matsuo, Yoshiharu Minamitake
-
Patent number: 9939446Abstract: A method for treating an individual at risk for a complement-associated disorder is provided, the method including: (a) obtaining a sample of a body fluid from the individual; (b) measuring a complement activation level in the sample via a point-of-care lateral flow immunoassay; (c) correlating the complement activation level in the sample to a risk of a complement-associated disorder by comparing the complement activation level in the sample to a reference level in a control, wherein a deviation in complement activation level in the sample compared to the reference level in the control indicates the individual is at risk for a complement-associated disorder; (d) selecting a treatment for the individual, based on the correlating of step (c); and (e) treating the individual with the treatment selected in accordance with step (d).Type: GrantFiled: August 13, 2015Date of Patent: April 10, 2018Assignee: Kypha, Inc.Inventors: Paul Olson, Don W. Moss
-
Patent number: 9932409Abstract: The present disclosure relates to a modified Interleukin-1 (IL-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the IL-1 family member cytokine is a mutant, more preferably it is a mutant IL-1 with low affinity to the IL-1 receptor, wherein said mutant IL-1 is specifically delivered to target cells. The targeting is preferably realized by fusion of the modified IL-1 family member cytokine to a targeting moiety, preferably an antibody or antibody-like molecule. The disclosure relates further to the use of such targeted modified IL-1 family member cytokine to treat diseases.Type: GrantFiled: July 4, 2014Date of Patent: April 3, 2018Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉMONTPELLIER 2, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIERInventors: Jan Tavernier, Sarah Gerlo, Frank Peelman, Gilles Uze
-
Patent number: 9920109Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing and purifying such molecules.Type: GrantFiled: August 19, 2013Date of Patent: March 20, 2018Assignee: Inhibrx LPInventors: Brendan Eckelman, John Timmer, Quinn Deveraux
-
Patent number: 9913879Abstract: The inventive subject matter relates to novel methods for modulating an immune response in an animal, which comprises administering to said animal an effective amount of an agent that increases IL-27R/WSX-1 activity. Further, the inventive subject matter relates to pharmaceutical compositions comprising an effective amount of an agent that increases IL-27R/WSX-1 activity.Type: GrantFiled: April 18, 2014Date of Patent: March 13, 2018Assignee: The Trustees of the University of PennsylvaniaInventors: Christopher A. Hunter, Alejandro Villarino